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ABSTRACT
Objective The UNAIDS Estimation and Projection
Package (EPP) is a tool for country-level estimation and
short-term projection of HIV/AIDS epidemics based on
fitting observed HIV surveillance data on prevalence. This
paper describes the adaptations made in EPP 2009, the
latest version of this tool, as new issues have arisen in
the global response, in particular the global expansion of
antiretroviral therapy (ART).
Results By December 2008 over 4 million people
globally were receiving ART, substantially improving their
survival. EPP 2009 required modifications to correctly
adjust for the effects of ART on incidence and the
resulting increases in HIV prevalence in populations with
high ART coverage. Because changing incidence is
a better indicator of program impact, the 2009 series of
UNAIDS tools also focuses on calculating incidence
alongside prevalence. Other changes made in EPP 2009
include: an improved procedure, incremental mixture
importance sampling, for efficiently generating more
accurate uncertainty estimates; provisions to vary the
urban/rural population ratios in generalised epidemics
over time; introduction of a modified epidemic model that
accommodates behaviour change in low incidence
settings; and improved procedures for calibrating
models. This paper describes these changes in detail,
and discusses anticipated future changes in the next
version of EPP.
INTRODUCTION: AN EVOLVING GLOBAL
RESPONSE DRIVES CHANGES IN UNAIDS TOOLS
The most signiﬁcant change in the global response
to HIV has been the rapid expansion of anti-
retroviral therapy (ART) using drug combinations
in developing countries. Since WHO and UNAIDS
launched the ‘3 by 5’ strategy in 2003,1 the number
of people on ART has grown to exceed 4 million
people by the end of 2008.2 High levels of ART in
many countries are now having a major impact on
HIV prevalence. Because survival of individuals on
ART is greatly prolonged, HIV prevalence in the
population as a whole will be higher than in the
absence of ART. These increased prevalence effects
are often reﬂected in surveillance data which the
UNAIDS Estimation and Projection Package (EPP)
ﬁts to the model developed by the UNAIDS
Reference Group on Estimates, Modelling and
Projections (hereafter, the Reference Group
model).3e6 EPP has been used extensively for
modelling national epidemics.7e10 The EPP model
must incorporate these effects of ART on preva-
lence before ﬁtting to the data. High levels of ART
can also lower the HIV incidence for a given
prevalence level through decreases in viral load
reducing individuals’ infectiousness. To respond to
both sets of treatment-related effects, EPP 2009
now uses a modiﬁed Reference Group model that
includes the impacts of ART on prevalence and
incidence.
Estimates of the number of persons living with
HIV have been the major focus of routine moni-
toring and reporting on HIV epidemics. However,
a number of problems have been identiﬁed with the
reliance on prevalence as an indicator for analysing
the impact of HIV programs. During the early
phases of an epidemic prevalence grows rapidly, but
changes in the slope due to saturation and to
program impact are difﬁcult to separate. After
several years HIV prevalence tends to plateau, with
new infections and deaths balancing each other
out. An effective program introduced as this
plateau phase begins may induce a gradual decline
in prevalence, but this decline may be difﬁcult to
distinguish from mortality-related declines. Several
years ago, the global epidemic entered a plateau
phase, with most countries in sub-Saharan Afri-
cadwhere the majority of people living with HIV
residedshowing stable or only slowly declining
HIV prevalence. As a result, in 2007 UNAIDS began
to focus more attention on new infections, that is,
incidence, as a more informative measure of global
progress.11 In response, the UNAIDS Reference
Group recommended that the tools UNAIDS
prepares to assist countries in analysing their
epidemics, EPP and Spectrum, shift to a focus on
incidence.12 This change was made in the 2009
version of the software, which still ﬁts prevalence
data, but provides incidence from the model along
with prevalence as outputs. Because incidence is
derived by ﬁtting prevalence, it reﬂects an averaged
national trend in new infections and may not
capture short-term rises and falls in incidence
occurring in speciﬁc groups or geographical areas.
EPP 2009 includes a number of additional
changes to resolve issues that have arisen in the
application of the package at country level. EPP
2007’s uncertainty estimation procedures evaluated
50 000e200 000 sets of Reference Group model
parameters for their ﬁt to the observed prevalence
data, normally selecting out 50 or more that were
close to the data (described in Brown et al5 and
Alkema et al13). In a few countries, the defaults set
in the uncertainty procedures produced relatively
few unique curves, leading to inaccurate estimation
of uncertainty. A new procedure, incremental
mixture importance sampling (IMIS), has been
introduced to solve this problem. In many African
countries the population has been rapidly shifting
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from rural to urban areas, but earlier versions of EPP assumed
ﬁxed urban and rural population sizes.12 EPP 2009 now allows
the urban/rural proportions to vary over time. In a small number
of countries, ﬁts to the data in EPP 2007 produced zero incidence
within a few years, a situation which has never been observed in
any country. A modiﬁed Reference Group model was developed
for use in these countries. Finally, user interface changes were
introduced to allow user input of the data needed for ART
calculations, improve overall calibration procedures, and support
the shift to an incidence basis.
INCORPORATING ART INTO THE REFERENCE GROUP MODEL
AND EPP FITS
The widespread availability of ART is altering the course of HIV
epidemics. People living with HIV who start ART have
substantially increased survival.14 As a result, HIV prevalence is
higher than it would be otherwise. Figure 1 illustrates the
impact that scaling up ART from 0% coverage among those in
need in 2005 to 100% coverage by 2015 would have on an
advanced epidemic. Prevalence increases slightly because fewer
people are dying from HIV-related causes. At the same time,
incidence declines because a substantial fraction of those living
with HIV are now on ART, which substantially reduces their
infectivity, that is, their ability to infect their partners. In EPP
2009, based on a review by Baggaley and colleagues (unpub-
lished), the default value for the infectivity of those on ART is
set at 0.11 of the infectivity of persons not on ART, but the user
can change this value on the User Preferences page. This ﬁgure
was based on an extensive review of the relative HIV trans-
mission probability of treated individuals compared to people
not eligible for ART, estimated from the best ﬁeld data available
at the time as 0.20, an 80% reduction in infectivity. This ﬁgure
was then adjusted for the average duration and relative infec-
tiousness of the stages of HIV infection to provide the 0.11 ﬁgure
for relative infectiousness compared to all infected individuals,
that is, both those eligible for and ineligible for ART. This value
is similar to those in another literature review and a recent
cohort study, both of which found a 92% reduction in hetero-
sexual transmission among those on ART relative to those not
on therapy.15 16
Adding ART to EPP 2009 required substantial changes to both
the internal Reference Group model and the user interface:
< The underlying equations describing the Reference Group
model were modiﬁed to include the effects of ARTon survival
and new infections (see the appendix).
< The EPP interface added an ART Data page for the user to
provide information about the CD4 eligibility criterion, HIV
progression rate and numbers on ﬁrst- and second-line ART.
< The Results page added a button, labelled ‘ARTresults’ which
brings up a table displaying the number of people on ARTand
estimated percentage of ART need met.
The original Reference Group model, described in detail
previously,4 5 divided the population into three groups: (1) those
not at risk (X); (2) those at risk, but not yet infected (Z); and (3)
those at risk and living with HIV (Y). These three groups are
shown in the upper left of ﬁgure 2. New members can enter the
two uninfected compartments at age 15 and only leave
a compartment by contracting HIV or dying. Those in the
uninfected compartments have only background mortality
applied, while those living with HIV also have additional HIV-
related mortality, which depends on when they contracted HIV.
As seen in the lower right of ﬁgure 2, the model in EPP 2009
has been modiﬁed to add several new compartments: those
newly eligible for ART, divided among those untreated and those
on ﬁrst-line ART; and those on second-line ART. While previous
versions of EPP and Spectrum used a single Weibull survival
function for time from infection to death, EPP 2009 and current
versions of Spectrum replaced this single function with four
functions: a Weibull curve describing progression from infection
to eligibility for ART, a second Weibull curve describing
progression from eligibility to death in the absence of ART (see
ﬁgure 3), and simple survival functions for those on ﬁrst- and
second-line ART expressed as the percentage of those on each
treatment surviving from year to year. The eligibility Weibull
function is used to progress people from the infected at-risk
compartment into the currently eligible compartment based on
their time since infection. EPP 2009 then uses current numbers
of people on ﬁrst- and second-line ART supplied by the user to
divide eligible individuals into those untreated, those on ﬁrst-line
ARTand those on second-line ART. For persons remaining in the
untreated category, survival will follow the Weibull distribution
of time from eligibility to death based on the time at which they
became eligible. For those on ﬁrst-line ART, survival is deter-
mined by two values: (1) the percentage surviving the ﬁrst year
on ﬁrst-line ART, and (2) the percentage surviving subsequent
a 
b 
Figure 1 The impact that scaling up to 100% of antiretroviral therapy
(ART) need by 2015 would have if begun in 2005 in an advanced
epidemic. (A) Prevalence increases as a result of prolonged survival of
those on ART, while (B) incidence declines. Note that the UNAIDS
Estimation and Projection Package (EPP) estimates incidence using the
traditional epidemiological definition of percentage of susceptibles
contracting HIV rather than on a whole-population basis.
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years on ﬁrst-line ART. By default these are set to 86% and 90%,
respectively, but may be changed by the user. If a person fails
ﬁrst-line therapy and slots are open for second-line therapy, they
are moved to second-line therapy and 90% survival per year is
assumed in subsequent years. If no slots are open, they progress
to death. By tracking people’s evolution through these addi-
tional compartments, the outputs of EPP 2009 incorporate the
impacts of ART on prevalence and incidence. The equations
describing this model are provided in the appendix.
The Weibull curves used depend on both an eligibility criterion
in terms of CD4 count and a fast or normal progression rate
from HIV infection to death chosen by the user: four sets of
Weibull parameters are provided to cover possible combinations
of CD4 eligibility threshold (CD4<200 and CD4<350) and
progression pattern (normal with median 11-year survival, fast
with median 9-year survival without ART). Fast and slow
progression patterns address the wide variability in survival
observed between African and Thai cohorts.17
This modiﬁed model requires several decisions and numerical
inputs from the user in order to fully calculate ART effects:
< CD4 eligibility threshold. The user must select eligibility for
ART as a CD4 count below 200 cells/mm3 or a CD4 below
350 cells/mm3.
< Progression pattern. The user must select a progression pattern
with an overall survival in the absence of ART of 11 years
(normal pattern) or one with survival of 9 years (fast
pattern).
< Year-by-year estimates of percentage survival in the 1st year of
ART. By default this is set to 86% surviving the ﬁrst year and
is kept at this value throughout the projection. However,
expansion of voluntary counselling and testing (VCT)
programs in most countries is expected to allow for detection
of individuals living with HIV at higher CD4 counts.
When therapy starts at higher CD4 counts, survival is
improved.18 19 As VCT programs expand, it is expected that
ﬁrst year survival will improve, so EPP and Spectrum allow
the user to change it over time.
< Year-by-year numbers on ﬁrst-line and second-line ART nationally.
The user must provide the total number of individuals on
ﬁrst- and second-line therapies. For years in the past, values
should be based on historical program data. For years in the
future, values can be based on projections of anticipated
numbers on ART. To simplify future projections, the user can
enter values for historical data and an estimate for the
numbers on ART in the ﬁnal year of the projection and then
select an option to project the intervening years (the ‘ART
project’ button). This will linearly extrapolate from the last
historical value entered and the estimate for the ﬁnal year.
< Distribution of ART among user deﬁned subpopulations. Finally,
the user must distribute the national ART numbers among
the different subpopulations. This distribution may be either
done in absolute numbers or as percentages of all those on
ARTwho are members of each subpopulation.
Figure 2 The compartments in the
modified Reference Group model with
antiretroviral therapy (ART) used in the
UNAIDS Estimation and Projection
Package (EPP) 2009. Once they
become eligible for ART, those living
with HIV can move to untreated or first-
line therapy compartments based on
the number of treatment slots available.
If they fail first-line therapy they can
move to second-line therapy.
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Figure 3 Example of the Weibull distributions for time (A) from
infection to antiretroviral therapy (ART) eligibility and (B) from ART
eligibility to death. When combined, they approximate (C) the original
Weibull survival function used in previous versions of the UNAIDS
Estimation and Projection Package (EPP) and Spectrum. This figure is for
a CD4 eligibility threshold of 200 cells/mm3 and normal (11-year
survival) progression pattern.
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The user enters this information on a single ART Data page in
EPP 2009. The subsequent year survival on ART is speciﬁed on
the User Preferences page and can be altered by the user if
desired, although the Reference Group generally recommends
against this in the absence of convincing local data to the
contrary.
THE SHIFT TO INCIDENCE
In EPP incidence is deﬁned using the standard epidemiological
deﬁnition of the percentage of those susceptible to infection
contracting HIV in a speciﬁed year. The shift from prevalence to
incidence in EPP 2009 required primarily changes in the user
interface. Internally, the EPP implementation of the Reference
Group model has always explicitly calculated incidence while
ﬁtting prevalence. For EPP 2009, however, this was made visible
to the user. There are a number of places where the shift to
incidence becomes apparent:
< The ﬁles containing the national projection and uncertainty
estimates (*.spt and *.spu) that EPP passes to Spectrum now
provide incidence as well as prevalence. Spectrum then uses
this incidence to calculate its outputs for national projections.
< On the Results page, incidence can now be displayed both in
terms of estimated number of new infections and percentage
of susceptibles contracting HIV in a given year (see ﬁgure 4).
Users should always take ﬁnal new and current infection
numbers from Spectrum rather than EPP because Spectrum
has a more complete demographic model, while EPP uses
a simpliﬁed demographic model inherent in the Reference
Group model.
< A graph for displaying the incidence distribution (see ﬁgure 5)
has been added to the Results page and is activated by
clicking the button labelled ‘Incidence distribution’. This
displays the distribution of incidence among the various user
deﬁned subpopulations in EPP. It can help to track the
evolution of the epidemic and provide countries with a better
idea of which populations are giving rise to new infections at
a given point in time.
IMPROVING UNCERTAINTY ESTIMATION
EPP 2007 adopted an uncertainty estimation method known as
Bayesian melding.5 13 This method generates random combina-
tions of the Reference Group model parameters (r, f0, t0 and 4) in
accord with user-speciﬁed distributions of each of the variables,
weights them by how well they ﬁt the surveillance data, and
then resamples them to provide an estimate of the uncertainty
in the ﬁt of the model to the data.20 This method worked fairly
well in most cases, but for some surveillance data sets the
method found relatively few unique curves close to the data
among the resamples (see ﬁgure 6A). This meant that the
uncertainty bounds were not very well-determined. The
problem could be alleviated by generating more parameter
combinations, but this was very computationally demanding
and time-consuming.
EPP 2009 replaced the simple random sampling of possible
combinations of variables in the Bayesian melding module with
a procedure known as incremental mixture importance sampling
(IMIS).21 22 In IMIS, a smaller initial set of (r, f0, t0 and 4)
combinations is generated. (Note: If one is using the 4-shift
described later in this paper, this group is expanded by two
variables, 49 and the year in which the shift begins, t4eshift.)
These are then evaluated and weighted by their ﬁt to the data.
New combinations of the variables are then generated centred
on the combination with the highest weight. This process is
repeated iteratively until the desired number of unique curves is
obtained. The IMIS algorithm has several control parameters:
the number of initial samples, N0, the sample size at each
importance sampling iteration, B, and the number of resamples,
J. The algorithm is unbiased for any choice of these parameters,
but they do affect its efﬁciency. After extensive experimentation,
good results were found with N0¼4000, B¼400 and J¼3000. For
3000 resamples, ﬁnding 1900 unique curves ensures the resam-
pled curves will be a good approximation to the actual distri-
bution, so this was set as the default for national projections. For
training purposes the number of unique curves was set at 400,
which allows ﬁts to be generated in a few minutes during
workshops. Figure 6B illustrates how this procedure has gener-
ated a much higher number of unique curves, making the
uncertainty bounds more accurate.
ALLOWING FOR URBAN/RURAL POPULATION SHIFTS
Urbanisation is a global phenomenon, and large urban/rural HIV
prevalence differentials are often observed in countries with
generalised epidemics.23 24 Across Africa, United Nations Popu-
lation Division projections show urban populations growing
Figure 4 Incidence display on the Results page. The user can select to display new infections, that is, incidence as either (A) the percentage of those
susceptible to infection who contracted HIV in the last year or (B) an absolute number of new infections in a year.
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from 27.6% in 1980 to 39.9% in 201025; and in a few countries
with generalised epidemics, the rate of urbanisation is extreme.
Between 1980 and 2010, Botswana went from 16.5% to 61.1%
urban, while Angola went from 24.3% to 58.5%.25 In an era of
increasing urbanisation, urban/rural prevalence differentials can
have a major inﬂuence on national HIVestimates.26 To adjust for
this inﬂuence, EPP 2009 allows for changes in the urban/rural
population proportions over time in generalised epidemics.
In most generalised epidemics, the national projection is
divided into two subpopulations: one urban and one rural. In
EPP 2009 the user ﬁrst ﬁts the epidemics in each subpopulation
to the corresponding HIV surveillance data. EPP 2009 then
combines these two separate ﬁts with weights proportional to
the number of people living in urban or rural areas. By default,
the urban percentage is set based on the numbers entered on the
Deﬁne Pops page and is kept constant over time. However, the
user can change the annual urban/rural proportions over time on
the Pop Change page, which contains a table showing the overall
percentage of urban population along with the percentage of
national population in each subpopulation. The user can also
adjust urbanerural proportions to the values provided by the
United Nations Population Division by clicking on an ‘Adjust to
UN values’ button. If the user has deﬁned multiple urban and
rural subpopulations, then the total urban population is divided
among them according to their relative size as speciﬁed on the
Deﬁne Pops page. The actual resulting population sizes and the
impacts on national HIV prevalence can then be examined on
the Results page.
UNUSUAL CASES FORCE MODIFICATIONS TO THE MODEL
One ﬁnal issue seen in the ﬁeld was a small number of data sets,
for example, in Cambodia or Zimbabwe, that approached zero
incidence by the end of the projection period when ﬁt with EPP
2007. No national HIV epidemic has ever been observed that
actually declined to zero incidence. The problem here is that
epidemics are dynamic, that is, the behaviours that drive them
can and do change over time. However, the Reference Group
model is static, that is, the four parameters that deﬁne the model
(r, f0, t0 and 4) are ﬁxed and do not vary over timedthey must ﬁt
both the early epidemic and the late epidemic. While the 4
parameter was introduced to represent increased or decreased
levels of risk behaviour over the course of the epidemic,6 it forces
a particular behaviour change pattern on a projection that is
Figure 5 Incidence distribution displays. UNAIDS Estimation and Projection Package (EPP) 2009 allows the display of the distribution of incidence
among the subpopulations comprising a national projection. The vertical axis shows the number of new infections in thousands.
Figure 6 A comparison of the outcomes of the Bayesian melding routines as implemented in the UNAIDS Estimation and Projection Package (EPP)
2007 (A) and EPP 2009 (B) with the same data set. This illustrates how the incremental mixture importance sampling (IMIS) procedure used in EPP
2009 provides many more unique curves and better uncertainty estimates in similar amounts of computational time.
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itself static. In the real world, behaviours change, the proportion
of people at risk changes, and any model with static parameters
will not be able to capture the full complexity. In fact, in a few
epidemics incidence is once again rising, something that the
original Reference Group model was never intended to reproduce
and which cannot be ﬁtted with the standard four-parameter
model.
In order to address these issues, a number of variants to the
Reference Group model were considered. One alternative
allowed for a one-time change in r, which represents the rate at
which new infections occur among the susceptible population.
However, this approach was found to be insufﬁcient, as the
change in r often occurred when there were no susceptibles left
in the population to become infected. Other alternatives were
also explored, including variants in which both r and 4 were
allowed to change, and in which r shifted gradually over some
time frame; but neither of these resolved the zero incidence
issues. The solution ﬁnally adopted was to allow a slow shift in
4 over some period before the end of the projection period. The
interpretation of this scenario is that as prevalence declines from
its peak, some individuals who had reduced their risk behaviours
in response to the epidemic, might return to riskier behaviours,
which would increase recruitment into the susceptible popula-
tion. By allowing such changes and applying constraints on
incidence, more reasonable incidence patterns could be produced
while still ﬁtting the data. This produced a six-parameter model
with (r, f0, t0 and 4) supplemented by a 49 and a year, t4eshift in
which 4 began a slow shift to 49 by the end of the projection
period. Using this approach, it was possible to ﬁt the more
problematic data sets without having incidence drop to zero (see
ﬁgure 7).
ANTICIPATED FUTURE DIRECTIONS
In the 2009 round of estimations, even after decomposing the
population in homogeneous groups (eg, urban/rural, provinces,
etc) more complex epidemic patterns were observed in a number
of countries, for example, an early peak and subsequent decline
in prevalence followed by an increase in prevalence. These
patterns almost certainly result from behavioural changes,
where lower levels of risk behaviour in the past are giving way to
higher levels today, producing higher incidence. Such changes
may result from prevention fatigue, perceptions of lower HIV
severity with the availability of ART, new generations of
susceptibles, or newly emerging epidemics in populations
previously unaffected. Addressing these will require a more
complex model than the simple four-parameter (r, f0, t0 and 4)
Reference Group model or even the new six-parameter 4-shift
model outlined above. Work is currently underway to develop
models that allow r to vary smoothly over time (described in
Hogan et al27 and in Bao and Raftery28), thus permitting the
combined SpectrumeEPP package to better handle the more
complex behavioural trends being observed as the global
pandemic enters its fourth decade.
The focus on incidence in this round of global estimates
highlighted some issues with the current separation of respon-
sibilities between EPP and Spectrum, with EPP ﬁtting the
prevalence data and Spectrum subsequently applying a more
complete age-structured demographic model to the resulting
prevalence curve to produce comprehensive national outputs.
Since incidence was calculated as the percentage of susceptible
individuals contracting HIV, the variations in their underlying
population models resulted in slightly different calculations of
the number of new infections between EPP and Spectrum. In
some countries, migration, which is included in Spectrum’s
demographic model but not in EPP ’s, made a substantial
difference in incidence levels. In addition, it became clear that
better incidence estimates would be obtained if the Reference
Group model was adapted to use a population between 15 and
49 years of age and allowed ageing out at 50, instead of the
current 15+ population. These factors also contributed to
differing ART estimates between the two models, sometimes
requiring countries to go through an iterative process to reach an
acceptable result. These problems are being addressed in the
next round of EPP and Spectrum by combining them into
a more tightly integrated package. EPP will take its demo-
graphics directly from Spectrum and will pass its incidence
calculations to Spectrum without direct user intervention, thus
ensuring better consistency. The user will actually invoke EPP
from within Spectrum, thus providing a more holistic user
experience.
In light of evolving global and national policies and recom-
mendations for initiation of ART at higher and higher CD4
counts, the next versions of Spectrum and EPP are adopting
a CD4 model allowing for a fuller range of CD4 criteria, for
example, 200, 250, 350 and 500.
Figure 7 An example of the impact of applying a 4-shift with an incidence constraint to Zimbabwe urban data. The left-hand figure shows the near-
zero incidence resulting from a four-parameter Reference Group model fit, while the right-hand side shows the results of allowing 4 to vary, providing
a low, but stable incidence pattern.
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The Reference Group also recognises that many countries rely
on case reporting systems as opposed to cross-sectional seros-
urveillance and has begun to explore methodologies for esti-
mating the levels of under-reporting in such systems as
diagnoses increase, but these discussions are still at an early
stage. In the future, as techniques for such estimation improve,
their incorporation into the UNAIDS estimation and projection
suite may be considered. As they have since the beginning, these
tools will continue to evolve to address new problems and issues
that arise as the global pandemic enters its fourth decade.
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APPENDIX
The mathematics of antiretroviral therapy (ART) in EPP 2009
The Reference Group model modifications used in EPP 2009 are shown in figure 2.
They primarily consist of calculating the number newly eligible for ART (E) at a given
time step, and then dividing these among two new compartments for those who
remain untreated (U) and those who go on first-line ART (L1). An additional
compartment is added for those failing first-line ART and going on second-line ART
(L2). The original compartments in the model are retained: not at risk (X), at risk and
infected but not on ART (Y), and at risk but uninfected (Z). The total population at any
point in time is then calculated as:
Key messages
< The UNAIDS Estimation and Projection package has contin-
ually evolved to adapt to new issues arising in estimating and
projecting national HIV epidemics.
< EPP 2009 derives incidence, an essential indicator for program
impact assessment.
< EPP 2009 includes the effects of ART: reducing incidence,
increasing prevalence and decreasing HIV-related mortality.
< Computational efficiency in EPP 2009 has been greatly
improved through the use of incremental mixture importance
sampling.
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N ¼ X þ Y þ Z þ U þ L1 þ L2
Demographic parameters, calculated from the United Nations Population Division
non-AIDS projections, include background mortality (m), birth rate to those aged 15
and older (b) and survival to age 15 (l). These are used along with the probability of
vertical transmission (n) and the fertility reduction among HIV+ women (3) to
calculate the number of new entrants Et in a given time step, t, in terms of the
populations 15 years (t15) earlier as:
Et ¼ Bt15l
Bt15 ¼ b

Xt15 þ Zt15 þ

1 n3Yt15 þ Ut15 þ L1ðt15Þ þ L2ðt15Þ
The four primary Reference Group parameters remain unchanged: the force of
infection (r), the initial fraction entering the at-risk population (f0), the start year of the
epidemic (t0) and the behaviour-change parameter (4); and the fraction, f, entering
the at-risk population at a given point in time is determined by the size of the not-at-
risk and total populations as:
f

X=N

¼ exp

f

X
N
 1 f0
exp

f

X
N
 1 f0 þ 1f0  1
To implement ART, a number of ART-specific inputs must be provided or selected
by the user:
< Time series for the number on first- and second-line ART: L1(t) and L2(t)
< The infectivity of individuals on ART relative to those not on ART: Rinf (default 0.11,
but user adjustable, Rinf¼0 means no transmission)
< Weibull for progression from infection to ART eligibility:
g1ðxÞ ¼ ða1xa11=ba11 Þexp½ðx=b1Þa1 
< Weibull for progression from eligibility to death if no ART:
g2ðxÞ ¼ ða2xa21=ba22 Þexp½ðx=b2Þa2 
< First year survival on first-line ART (time varying): s1(t) (default 86%, held constant,
but user can change on an annual basis)
< Second and subsequent year survival on both first- and second-line ART: s2+
(default 90%, but user adjustable)
The latter two survivals are then used to calculate a third distribution for
progression to first-line failure once ART has commenced:
g3

x
 ¼
( 0 if x ¼ 0
s1e
s1x if x#1yr
s2þ es1es2þ ðx1Þ if x > 1yr
EPP then calculates the distribution for the rate at which infections occur at time
x as:
Ynewx ¼ ½ðr½Yx þ Ux þ RinfðL1x þ L2xÞ=Nx þ ixÞZx;
where ti is the pulse of infection that initiates the epidemic. Note that those on ART
receive the reduced infectiousness described by Rinf. The equations describing the
changes in the number in each of the compartments: X, Y and Z becomes:
DX ¼ ½ð1 fðX=NÞÞEt  mXDt
DY ¼
h
r

Y þ U þ Rinf

L1 þ L2
i.
N þ i

Z
Zt
0
Ynewx g1

t xdx mYiDt
DZ ¼ ½fðX=NÞEt  ðm þ r½Y þ U þ RinfðL1 þ L2Þ=N þ iÞZDt
And the number newly eligible for ART in a given time step is calculated from the
progression from infection to eligibility and the temporal distribution of new infections:
DE ¼
2
4Zt
0
Ynewx g1

t xdx
3
5Dt
The newly eligible must then be allocated into the compartments for those on first-
line treatment (L1) and those remaining untreated (U). The number failing first-line ART
is calculated by applying the g3(x) distribution to estimate the number who fail first-
line therapy, and thus leave the L1 compartment:Zt
0
Lnew1x g3

t xdx
Where Lnew1x is the number who entered first-line therapy at time x. L
new
1x is kept at zero
until ART is initiated. The number failing first-line therapy is then combined with the
user-provided time series L1(t) and L2(t), for numbers on first-line and second-line ART,
to calculate the number entering each arm of ART at the next time step as:
Lnew1 ¼
h
L1

t þ Dt

 L1

t
i
þ
Zt
0
Lnew1x g3

t xdx
Lnew2 ¼

L2

t þ Dt L2t þ 1 s2þ L2tDt
that is, the number newly entering first-line ART is the increase in numbers on first-
line ART specified by the user plus replacements for those who fail on ART. For
second-line therapy, it is assumed that a constant fraction of those currently on ART
fail at every time step, the second term in the above equation. The remaining number
of newly eligible must then be allocated into the untreated compartment, U:
DU ¼ DE Lnew1 
h
mU þ
Zt
0
UnewAdjx g2

t xdxiDt
The final term in brackets in this equation represents background mortality (mU)
and HIV-related mortality for those remaining untreated through the present. UnewAdjx is
the distribution of the number untreated who became eligible for ART at time x. When
people are placed on ART at each time step, this distribution must be adjusted
downward to account for the fraction of the untreated going on to ART and also to
correct for background mortality:
UnewAdjx

t þ Dt ¼ UnewAdjx t

1 L
new
1
UðtÞ
	
1 mDt
This effectively assumes that those selected for ART are chosen uniformly without
regard to their duration of infection. If all of those eligible at any point in the projection
are placed on ART, this distribution is set to zero for all previous times. The total
number living with HIV in the population is then defined as:
Hþ ¼ Y þ U þ L1 þ L2
which accounts for the effects of ART on total HIV prevalence and incidence.
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